Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors
Emiel Leegwater, Anne S. Strik, Erik B. Wilms, Liesbeth Bosma, David M. Burger, Thomas H. Ottens, Cees van Nieuwkoop
Abstract
We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.
Topics & Concepts
GlycoproteinMedicineCoronavirus disease 2019 (COVID-19)Liver injuryP-glycoproteinCoronavirusDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDrugMedical prescriptionPharmacologyVirologyInternal medicineInfectious disease (medical specialty)ChemistryBiologyDrug resistanceMultiple drug resistanceMicrobiologyOutbreakBiochemistryDrug-Induced Hepatotoxicity and ProtectionCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research